Beacon Therapeutics is an ophthalmic gene therapy company founded in 2023 to restore and improve the vision of patients with a range of prevalent and rare retinal diseases that result in blindness.
The Company has an established scientific foundation that combines a late-stage development candidate to treat X-linked retinitis pigmentosa (XLRP) with two preclinical programs, one targeting dry age-related macular degeneration (AMD) and another in-licensed from the University of Oxford targeting cone-rod dystrophy (CRD).
Beacon Therapeutics also has access to a target generation technology platform that will identify, screen and search secreted proteins in the ophthalmology space.
The Company is supported by funds from Syncona and additional investors including Oxford Science Enterprises.
Beacon Therapeutics is led by an experienced management team with decades of gene therapy and ophthalmic experience.